Amicogen, Inc. Overview
Bases: FY2024 is company IR (Q2 2024); FY2025 is PitchBook; FY2026 is THE VC (June 2026, pension-registry basis). Google Finance shows 236.
Amicogen is a Jinju-based industrial biotechnology company. It was built on directed-evolution ("gene evolution") enzyme engineering. Its proprietary techniques, RCM™ point mutagenesis and RETT™ recombination, underpin pharmaceutical-grade special enzymes such as CX, SP and SC. These enzymes convert chemical antibiotic-intermediate processes (7-ACA, 7-ADCA) into greener enzymatic or fermentative routes. On that core it layered three further businesses:
-
enzyme-derived health-functional ingredients (NAG, PI/DCI, collagen peptides);
-
bioprocess consumables, namely chromatography resins via Puriogen and cell-culture media from a Songdo plant, positioned as Korea's only simultaneous domestic producer of both;
-
early-stage biopharma assets, including a non-PH20 human hyaluronidase.
Between 2015 and 2024 most consolidated revenue came from Amicogen China's veterinary and human APIs. The 48.78% sale of Amicogen China in December 2024 shrank reported revenue by roughly three-quarters. The company is now a small, loss-making, governance-in-transition business. It depends on external capital to commercialise its media and resin capacity.
Company's own description
In its 2025 investor presentation, Amicogen describes itself as an industrial-biotech company. Its technology areas are gene evolution, biocatalysis and microbial metabolic engineering. Its main products are listed as pharmaceutical special enzymes (CX enzyme, SP and others) and bio-new-materials (N-acetylglucosamine, DCI/PI, collagen peptide, fucoxanthin and others). It frames its business in four pillars: Enzyme & Biopharma, Bio-Pharmaceutical Parts & Materials, Media & Resin, and Healthcare [S-IR25]. Its corporate tagline is "sustainable growth of humans and nature" [S-IR25].
Independent characterisation
Amicogen is best understood as four businesses at very different maturity stages sharing one balance sheet:
-
Enzymes & Green API (cash-generating core).
-
CX enzyme is a biocatalyst for 7-ACA, the cephalosporin intermediate. Historically it was sold almost entirely to Chinese 7-ACA producers.
-
SP enzyme serves penicillin-class API synthesis. SC enzyme serves cephalosporin API synthesis.
-
"DX" strain/fermentation technology licences generate royalties. In 2020 DX technology was transferred to a Chinese partner producing over 1,000 t/yr of 7-ADCA. The company says this yields KRW 2–3bn of recurring royalties per year. CPC strain transfer was completed in 2023 [S-ASIA-DX].
-
-
Healthcare ingredients and finished products.
-
NAG (joint and skin individually-recognised functional ingredient), PI/DCI, collagen peptide (CP) and collagen tripeptide (CTP), chitosan oligosaccharide, grain fermentation enzymes.
-
Sold B2B and through ODM to Korean pharma and food companies.
-
Sold B2C through the K-Nutra brand, launched December 2012 [S-KIRS].
-
-
Bioprocess consumables (growth bet, sub-scale).
-
Chromatography resins (Protein A/G/L affinity; IEX S, Q, CM, DEAE; HIC; SEC) are made by Puriogen in Yeosu.
-
Cell-culture media (powder and liquid CHO media, custom media, CDO services) are made in Songdo.
-
Protein A ligands are produced at Jinju [S-IR25], [S-KIRS].
-
-
Pipeline / platform assets (pre-revenue).
-
A novel skin-derived human hyaluronidase engineered for activity at neutral pH, aimed at IV-to-subcutaneous conversion of biologics.
-
Affinity ligands, including AAV-vector ligands.
-
Endolysin, with Germany's Lysando [S-IR25], [S-SUPPLE].
-
Business and revenue model
Product sales: dominate: enzymes, ingredients, finished health foods, resins and media.
Licensing/royalty: DX technology royalties and milestone-based consignment development fees. A February 2025 contract with a global antibiotic-API leader pays development milestones, then success and running royalties [S-ASIA-DX].
Services: media CDO (cell-line development, process development, media development) and custom media manufacturing [S-IR25].
Subscription: none.
A precise product/licensing split is not publicly disclosed at consolidated level. Royalties were estimated at KRW 4–5bn for FY2023 [S-KIRS].
Value chain position and customers
-
Upstream supplier of biocatalysts and intermediates to antibiotic API makers, chiefly in China, with India targeted.
-
Upstream supplier of process consumables to biologics manufacturers and CDMOs. Samsung Bioepis's CEO attended the June 2024 plant opening, and the media national project counted Korean biologics makers ("C" and "S") as demand-side participants [S-MG24], [S-IR25].
-
B2B ingredient supplier to health-food brands, for example FromBio's collagen launch in 2023 and Russia's Invita [S-KIRS], [S-DEAL7].
-
B2C via K-Nutra, including exports to Kazakhstan [S-ASIA-COL].
End-markets
Antibiotic APIs (human and, through the former subsidiary, veterinary), biologics and biosimilar manufacturing, nutraceuticals and inner-beauty, and cosmetics (endolysin-based skin microbiome products via partner Lysando).
Strategy
Stated strategy themes (paraphrased)
From the 2023 rights issue:
-
expand enzymes and biopharma into India and Southeast Asia;
-
grow global share of healthcare ingredients;
-
reach 30% domestic share in media and resins [S-DEAL3].
From the June 2024 plant opening:
-
secure 10x or more capacity for overseas media and resin markets;
-
enter the purification-ligand market (company-sized at over KRW 2 trillion);
-
take special enzymes and DX strains into Europe, India and Japan antibiotic markets;
-
enter human hyaluronidase (company-cited market of KRW 16 trillion by 2036) [S-PR24].
After the 2024 restructuring:
-
simplify the group by selling or liquidating non-core affiliates;
-
concentrate on enzymes/biopharma, healthcare, and media/resin [S-ASIA-BIF].
After the 2025 governance change:
-
stop investing in unfocused subsidiaries;
-
normalise management, then bring in a strategic investor;
-
shareholder-friendly measures, namely electronic voting and regular IR [S-DAUM2], [S-FN25].
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Source |
|---|---|---|---|
| Amicogen China stake sale | Dec 2024 | KRW 54.7bn proceeds earmarked for special enzymes, Green API, Green NAG, ligands and bioprocess enzymes; remaining 14.36% expected to gain value on a China IPO | [S-DEAL4] |
| DX consignment development | Feb 2025 | Milestones plus royalties from a global antibiotic leader | [S-ASIA-DX] |
| Hyaluronidase platform | Apr 2025 – 2026 | Patent filing; two Korean patent decisions; plans for global co-development or licence-out | [S-IR25], [S-SUPPLE] |
| Resin channels | Apr–Jul 2025; 2026 | Bio-Works OEM (KRW 1bn initial, 3bn+ potential annual sales); Zenmindes China; Aruni India | [S-ASIA-BW], [S-FN-ZEN], [S-VC-P] |
| Collagen exports | 2,025 | Raw material and finished goods; Kazakhstan launch | [S-ASIA-COL] |
| Government projects | 2025–2026 | Ministry of Health essential-medicine supply project; Ministry of Agriculture K-bioFEED peptide media project (Chonnam National University lead) | [S-FN-MAFRA] |
| Capex reset | 2025–2026 | Endolysin cGMP changed from new build to extension | [S-SIDAE] |
| Strategic investor search | Apr–Aug 2026 | Preferred-bidder process (Apr); YK Bionova deal (Jun) failed (Aug); new search under way | [S-VC-P], [S-DEAL8] |
| Cost programme | 2024–2025 | Process efficiency and closure of non-core units; no quantified target disclosed | [S-ASIA-3Q24] |
ESG / sustainability commitments
Positioning centres on "Green API", meaning enzymatic or fermentative processes replacing chemical synthesis. No quantified ESG targets were found.
Medium-term guidance
No formal financial guidance is published. Historic aspirational targets (domestic media/resin share of 30%.
Products & Services
Enzyme & Biopharma
| Product | Description / capabilities | Target customer | Year / status | Pricing | Source |
|---|---|---|---|---|---|
| CA enzyme | Immobilised enzyme for 7-ACA | Antibiotic API makers | Developed 2003; licensed to European MNC 2004 | — | [S-KIRS] |
| CX enzyme (flagship) | Biocatalyst for 7-ACA (cephalosporin intermediate). Company claims superiority in yield, cost and environmental burden versus chemical routes. Immobilised, high-activity. | Chinese 7-ACA producers; India targeted | Exports since 2011 | — | [S-KIRS], [S-IR25] |
| SP enzyme | Biocatalyst for penicillin-class API synthesis | API makers | Commercial | — | [S-KIRS] |
| SC enzyme | Biocatalyst for cephalosporin API synthesis | API makers | Commercial | — | [S-KIRS] |
| DX technology (DX0, DX2) | Direct-fermentation strains for CPC / 7-ADCA / 7-ACA, removing process steps | Global and Chinese antibiotic makers | DX2 commercial 2020; DX0 2023; new consignment deal Feb 2025 | Royalty and milestones | [S-ASIA-DX] |
| Green API enzyme programmes | About 10 cephalosporin API enzymatic processes under licensing or testing | API makers | Development | — | [S-ASIA-BIF] |
| Bioprocess enzymes | Enzymes for biomanufacturing | Biologics makers | Launched 2024 | — | [S-ASIA-2Q24] |
| Protein A / affinity ligands | Engineered Z-domain variants for alkali tolerance, mild-pH elution and impurity removal; AAV-vector ligands | Resin makers incl. Puriogen | Commercial (ligand sales) and development | — | [S-IR25] |
| Human hyaluronidase (non-PH20) | Skin-derived human enzyme engineered for neutral-pH activity, thermal stability and low immunogenicity. Positioned as free of PH20 patent constraints. | Biologics developers (SC formulation) | Patent filed Apr 2025; two Korean patent decisions 2026; pre-clinical | Licensing intended | [S-IR25], [S-SUPPLE] |
| Endolysin | Bacteriophage-derived lytic enzymes against resistant bacteria; high-production strain developed with Lysando | Pharma / cosmetics | Development; investment scaled down 2025–26 | — | [S-KIRS], [S-SIDAE] |
Bio-pharmaceutical materials (Media & Resin)
| Product / service | Description | Capacity / spec | Status | Source |
|---|---|---|---|---|
| Puriose® / Puriogen Protein A, G, L affinity resins | Antibody capture. Company tests claimed 81% (ProA) and 110% (ProG) higher purification capacity than competitors. | Yeosu plant: 10,000 L/yr, expansion target 50,000 L by 2027 | Plant completed May 2024 | [S-KIRS], [S-IR25] |
| HiPureA™ | Next-gen Protein A resin co-developed with Inha University. Published results show >98% recovery under mild-acid elution and reduced HCP/HCD impurities. | — | Published June 2026 | [S-FN-HIP], [S-DAILYBYTE] |
| IEX resins (S, Q, CM, DEAE) | Ion-exchange. Claimed 34% higher purification rate and 18% better flow durability versus competitors in tests at 8 companies. | — | First commercial order in India via distributor Aruni (2026) | [S-KIRS], [S-VC-P] |
| HIC, SEC, Oligo(dT), dual-function resins | Full chromatography portfolio, including mRNA (oligo-dT) and two-step-in-one resins | — | Portfolio | [S-IR25] |
| Cell-culture media (CHO, custom, Ultimax) | Powder and liquid; serum-free and chemically defined; ISO 9001/13485; GMP compliance; WFI/PW | Songdo: 106 t/yr powder, 4.16M L liquid, stated revenue-equivalent ~KRW 300bn. IR deck cites powder capacity of 100–320 t across batch lines of 20 kg / 300 kg / 1,000 kg. | Plant completed Mar 2024; supply talks with 11+ companies (2025) | [S-MG24], [S-IR25] |
| Media CDO services | Cell-line development, process development, media development, rapid prototyping, regulatory support for supplier change | — | Offered | [S-IR25] |
Healthcare
| Product | Description | Approvals / status | Source |
|---|---|---|---|
| NAG (N-acetylglucosamine) | Joint and skin moisture ingredient; enzymatic "Green NAG" process in development | MFDS individually-recognised 2005, 2008 | [S-KIRS], [S-DEAL4] |
| PI / DCI (pinitol / D-chiro-inositol) | Blood glucose, liver health, PCOS | MFDS 2005 (glucose), 2019 (liver) | [S-KIRS] |
| Collagen peptide (CP) | Enzymatic hydrolysate from fish skin | Capacity: Jinju 400 t; Qingdao 800 t (per 2023 statement); Vietnam 780–800 t (expandable to 2,400 t) | [S-DEAL7], [S-ASIA-COL] |
| Collagen tripeptide (CTP, "low-molecular collagen peptide AG") | GPH-rich tripeptide | MFDS individually-recognised Mar 2023 | [S-KIRS], [S-DEAL7] |
| COS (chitosan oligosaccharide), chitosan, Kiclean | Respiratory health research | Research / commercial | [S-KIRS], [S-IR25] |
| Grain fermentation enzymes; BP2 spore probiotic | Digestive | Commercial (ODM) | [S-KIRS], [S-ASIA-2Q24] |
| CureZyme-ACE (Acetobeta), CureZyme-LAC | Hangover; lactase | Clinical / FDA ODI work (2025 plan) | [S-IR25] |
| Compound K, carob syrup/powder, seed fermentation | Skin/cognition; glucose and weight | Research | [S-IR25] |
| Fucoxanthin | Listed among main products | Commercial | [S-IR25] |
| K-Nutra finished goods | Online, open market, telemarketing; exports such as K-COLLAGEN JELLY BERRY and COLLAGEN VITA C BERRY to Kazakhstan | Launched 2012; exports from May 2025 | [S-KIRS], [S-ASIA-COL] |
| Daily Pinitol 600 | Carob-derived pinitol 600 mg drink, described as a domestic first | Launched Sep 2026 | [S-DAILYBYTE] |
Pricing models are not publicly disclosed for any product line.
Financial Narrative
Basis: K-IFRS consolidated. FY2021–FY2025 headline figures come from OpenDART via [S-BULL]. FY2021–FY2022 detail comes from the Korea IR Council report [S-KIRS]. FY2025 is restated in scope because of Amicogen China's deconsolidation.
Income statement (KRW 100M)
Sources and caveats:
-
FY2025 gross profit is derived from Simply Wall St (revenue KRW 42.0bn less cost of revenue KRW 36.7bn) [S-SWS].
-
FY2025 operating loss is KRW 17.1bn per DART-based data [S-BULL]. A press report gives KRW 16.9bn [S-SIDAE]. Both are noted.
-
FY2024 dividends are presumed zero; no dividend was found. KIRS records DPS of 0 for 2019–2023 [S-KIRS].
EPS: FY2021 KRW 89 and FY2022 KRW –1,107, both on pre-2023-bonus-issue share counts [S-KIRS]. Aggregators show TTM EPS of KRW –121 (Google) and –425 (Simply Wall St), which conflict. Diluted EPS is not publicly verified.
Margins (%)
Revenue CAGR: FY2021–FY2024 is about +11.6% on a like-for-like consolidated scope. FY2021–FY2025 is about –23.8% because of deconsolidation and is not meaningful.
Quarterly run-rate after deconsolidation (KRW 100M)
Sources: [S-ETF], [S-GOOG].
-
The four 2025 quarters reconcile to the FY2025 totals.
-
Q1 2026 net income of +KRW 19.4bn is reported by an aggregator. H1 2026 net income is roughly breakeven (about –KRW 1.4bn).
Balance sheet (KRW 100M)
Sources: [S-KIRS] for FY2021–FY2022.
-
FY2024 equity is derived: the Bifido claim of KRW 11.7bn was disclosed as 9.5% of equity [S-DEAL6].
-
Convertible bonds sat in "other current liabilities" (KRW 83.2bn in FY2021; KRW 124.0bn in FY2022) and are not included in the borrowings rows.
-
Point data: at end-Q2 2024, cash was KRW 23.5bn against borrowings of about KRW 78bn [S-DEAL6]. In late 2023 the debt ratio was 163.8% and borrowing dependence 36.1% [S-ASIA-RI23].
Cash flow (KRW 100M)
Sources: [S-BULL] for OCF; [S-KIRS] for capex, FY2021–FY2022 equity and FY2023 rights issue.
-
FY2025 equity raised: a KRW 30bn public offering was announced in December 2025. The increase in share count to about 70.66M is consistent with completion [S-ASIA-RI], [S-GOOG].
-
No buybacks were found. Treasury stock was 202,129 shares (1%) at September 2023 [S-KIRS].
Ratios
Sources: [S-KIRS]; FY2023 debt ratio [S-ASIA-RI23]; FY2025 ROE is TTM as of December 2025 [S-KOALA].
-
Net debt/EBITDA in FY2022 was about 8x on KIRS data (net debt ≈ 92.7% × 1,698 ≈ 1,574; EBITDA 78), indicative only.
-
The cash conversion cycle is not disclosed. Receivables turnover fell from 5.5x (FY2021) to 3.4x (FY2022) [S-KIRS].
Commentary on trends, inflections and drivers
FY2021–FY2024: revenue growth without profit. Consolidated revenue grew from KRW 124.9bn to KRW 173.6bn, almost entirely through Amicogen China. That subsidiary's revenue rose 24.9% in FY2022 to KRW 107.3bn on API and finished-drug demand [S-KIRS]. It then added high-margin veterinary products such as tulathromycin (gross margin above 90%) and ceftiofur, which alone generated KRW 18.9bn in H1 2023 [S-DEAL9], [S-TOMATO].
Group operating income stayed near zero or negative in every year except FY2023. Three drivers explain this:
-
cost inflation and inventory and receivable provisions in FY2022;
-
start-up costs of the media and resin plants from 2024;
-
R&D spread across many affiliates [S-KIRS], [S-ASIA-2Q24].
Below-the-line losses dominate. Net losses consistently exceeded operating losses because of the "open innovation" investment book. FY2022 included KRW 11.2bn of Cellid valuation losses, KRW 6.7bn on Clinomics and KRW 19.4bn of equity-method losses on Bifido [S-KIRS]. FY2024's KRW 50.9bn net loss coincided with Q4 2024 (net loss KRW 38.7bn [S-ETF]).
FY2025 inflection: scope collapse. Deconsolidating Amicogen China removed about KRW 110–120bn of annual revenue. FY2025 revenue fell to KRW 42.0bn and the operating loss widened to KRW 17.1bn. The remaining enzyme, healthcare and media/resin business runs at low gross margin (about 13%). That margin carries fixed costs of two new plants with low utilisation.
FY2026 green shoots. Q2 2026 revenue of KRW 13.4bn was up about 33% year on year. The operating loss narrowed to KRW 1.3bn, the best quarterly result since the deconsolidation [S-ETF]. Whether this reflects media and resin commercialisation or one-offs cannot be determined from available data.
Cash. Operating cash flow was negative in three of five years. Cumulative OCF over FY2021–FY2025 was about –KRW 43.4bn while capex exceeded KRW 90bn in FY2021–FY2022 alone. The gap was bridged with CBs, an EB, two rights issues, asset sales (Bifido, Amicogen China, Seoul office, land parcels) and a related-party loan from Bifido [S-KIRS], [S-ASIA-BIF].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement (KRW)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW 100M) | 1,249 | 1,443 | 1,599 | 1,736 | 420 |
Gross profit (KRW 100M) | 449 | 460 | — | — | 53 |
Operating income (KRW 100M) | -46 | -49 | 21 | -71 | -171 |
EBITDA (KRW 100M) | 62 | 78 | — | — | — |
Pre-tax income (KRW 100M) | 97 | -506 | — | — | — |
Net income (KRW 100M) | 47 | -458 | -207 | -509 | -304 |
Net income to controlling holders (KRW 100M) | 37 | -472 | — | — | — |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 36.0 | 31.9 | — | — | 12.6 |
Operating margin (%) | -3.7 | -3.4 | 1.3 | -4.1 | -40.8 |
EBITDA margin (%) | 4.9 | 5.4 | — | — | — |
Net margin (%) | 3.8 | -31.7 | -12.9 | -29.3 | -72.3 |
Income Statement (KRW) (Quarterly)
| Metric | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|---|
Revenue (KRW 100M) | 108 | 101 | 101 | 109 | 123 | 134 |
Operating income (KRW 100M) | -43 | -42 | -47 | -39 | -32 | -13 |
Net income (KRW 100M) | -58 | -60 | -130 | -55 | 194 | -208 |
R&D expense (KRW 100M) | — | 20 | 16 | 22 | 14 | — |
SG&A (KRW 100M) | — | 26 | 26 | 30 | 33 | — |
Balance Sheet (KRW)
| Metric | FY2021 | FY2022 | FY2024 |
|---|---|---|---|
Total assets (KRW 100M) | 4,112 | 4,297 | — |
Cash & equivalents (KRW 100M) | 269 | 202 | — |
Short-term investments (KRW 100M) | 187 | 165 | — |
Short-term borrowings (KRW 100M) | 419 | 384 | — |
Long-term borrowings (KRW 100M) | 68 | 492 | — |
Total liabilities (KRW 100M) | 1,784 | 2,599 | — |
Total equity (KRW 100M) | 2,329 | 1,698 | 1,232 |
Intangible assets (KRW 100M) | 212 | 174 | — |
Current assets (KRW 100M) | 1,237 | 1,439 | — |
Current liabilities (KRW 100M) | 1,605 | 2,052 | — |
Working capital (KRW 100M) | -368 | -613 | — |
Cash Flow (KRW)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW 100M) | 81 | -224 | 86 | -133 | -244 |
Capex (KRW 100M) | -473 | -459 | — | — | — |
Free cash flow (KRW 100M) | -392 | -683 | — | — | — |
Dividends paid (KRW 100M) | 0 | 0 | 0 | 0 | 0 |
Equity issued (KRW 100M) | 224 | 1 | 703 | — | — |
Buybacks (KRW 100M) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2025 |
|---|---|---|---|---|
ROE (%) | 2.2 | -29.7 | — | -44.9 |
ROA (%) | 1.4 | -10.9 | — | — |
ROIC (%) | -3.3 | -4.8 | — | — |
Current ratio (%) | 77.1 | 70.2 | — | — |
Debt-to-equity, liabilities/equity (%) | 76.6 | 153.1 | 163.8 | — |
Net debt / equity (%) | 27.2 | 92.7 | — | — |
Interest coverage (x) | -1.6 | -0.7 | — | — |
Asset turnover (x) | 0.4 | 0.3 | — | — |
Revenue by Region (KRW)
| Geography proxy | FY2021 | FY2022 | FY2025 |
|---|---|---|---|
China via Amicogen China (KRW 100M) | 859 | 1,073 | 0 |
Korea parent and other subsidiaries, residual (KRW 100M) | 390 | 370 | 420 |
Share Price History
| Date | Price (KRW) |
|---|---|
20 Dec 2023 | 7,060 |
2 Jul 2024 (founder purchase price) | 5,094 |
1 Dec 2025 | 2,840 |
22 Dec 2025 (limit-down) | 1,945 |
Mar 2026 (approx.) | 1,400 |
10 Aug 2026 | 1,065 |
18 Sep 2026 | 907 |
6 Oct 2026 | 986 |
Valuation Multiples
| Multiple | Amicogen | Note |
|---|---|---|
Market cap (KRW 100M) | 696 | At KRW 985 [S-BUT] |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA (inferred from OP –171 in FY2025) |
P/S, FY2025 (x) | 1.66 | 696 / 420 |
P/S, TTM Q3-25 to Q2-26 (x) | 1.49 | 696 / 467 |
P/B (x) | 0.59 | [S-BUT] |
EV/Sales | Not computed | — |
Capital Instruments
| Instrument | Date | Amount (KRW) | Terms |
|---|---|---|---|
CB #1 (private) | Jun 2021 | 50bn | Conversion KRW 41,552 → 29,087 (refixed); put from 29 Dec 2023; addressed by 2023 rights issue |
Third-party allotment (Lysando swap) | Sep 2021 | 22.3bn | Share exchange |
EB #2 | May 2022 | 8.7bn | Exchangeable into Cellid shares |
CB #3 | Jul 2022 | 40bn | — |
Rights issue plus 1:1 bonus issue | Sep–Dec 2023 | ~70.3bn | Final price KRW 9,130 |
Related-party loan from Bifido | 2024 | 15bn borrowed; 11.7bn under suit | — |
General public offering | Dec 2025 – early 2026 | 30bn (planned) | — |
Third-party allotment (YK Bionova) | Jun 2026 | 10bn | Failed |
Analyst Conclusions
Management guidance
There is no quantitative guidance. Recent management messaging (2024–2026) has emphasised:
-
enzyme recovery (antibiotic market and India);
-
healthcare exports;
-
media and resin commercialisation through domestic and overseas channels;
-
strategic-investor selection with "reliability and stability" as criteria [S-ASIA-3Q24], [S-DEAL8].
Consensus
No sell-side consensus exists. An independent model (KoalaGains) assumes a revenue CAGR of about 6% for FY2024–FY2028 with persistent losses. That model predates the FY2025 scope change and should be treated as stale [S-KOALA-F].
Bull case
-
Operating inflection is visible.
-
Q2 2026 operating loss narrowed to KRW 1.3bn, from KRW 4.2bn a year earlier.
-
Revenue grew about 33% year on year to KRW 13.4bn [S-ETF].
-
With the plants already built, incremental media and resin volume falls through at high marginal margins.
-
-
Hidden asset value.
-
P/B is about 0.59x [S-BUT].
-
Assets include a retained 14.36% Amicogen China stake (company hope: KRW 50bn+ on a China listing), a Puriogen stake (externally funded at Series B), and the Lysando and Ropi Bio stakes [S-DEAL4], [S-VC-P].
-
-
Platform optionality.
-
Non-PH20 hyaluronidase with fresh Korean patent decisions [S-SUPPLE].
-
Granted Protein A ligand IP.
-
DX royalty expansion [S-ASIA-DX].
-
Bear case
-
Funding treadmill.
-
OCF was –KRW 24.4bn in FY2025 [S-BULL].
-
A failed KRW 10bn placement shows a weak capital-access position.
-
Further dilution at about KRW 1,000/share is likely.
-
-
Governance risk.
-
There is no anchor shareholder (largest holder about 5% before 2025–26 dilution).
-
Repeated control-transfer attempts and report amendments.
-
Unresolved KRW 11.7bn litigation [S-DEAL5], [S-DEAL8], [S-DEAL6].
-
-
Commercial proof is thin.
-
Media and resin revenues remain undisclosed and appear small; the Bio-Works OEM's initial annual sales were guided at only KRW 1bn [S-ASIA-BW].
-
The two plants' headline capacities (KRW 300bn of media; KRW 40bn of resin) dwarf current group revenue of KRW 42bn [S-MG24].
-
Catalysts and monitorables (next 12 months)
-
Selection of a new strategic investor or control buyer, and the outcome of the August 2026 EGM agenda.
-
Q3 2026 results (mid-November 2026): whether operating breakeven approaches.
-
Disclosure of media and resin customer qualifications or supply contracts, especially with Korean CDMOs.
-
Bifido lawsuit ruling or settlement.
-
Hyaluronidase partnering or licence-out.
-
Progress toward Amicogen China's China IPO.
-
Puriogen financing and any listing plan (duplicate-listing rules).
-
Any KOSDAQ administrative-issue designation triggers based on loss metrics.
-
FY2026 audit opinion and going-concern language.
Concluding analyst verdict
Amicogen today is a fundamentally different company from the one that reported KRW 173.6bn of revenue in FY2024. The sale of control of Amicogen China removed roughly three-quarters of revenue and the group's only reliably profitable large operating unit. What remains has four parts:
-
a genuinely differentiated enzyme-engineering franchise, which produces modest product sales plus recurring DX royalties;
-
a commoditising healthcare-ingredient business;
-
two newly built, under-utilised bioprocess plants;
-
a scatter of minority stakes left over from an aggressive decade of "open innovation".
On the evidence, the technology is real. Granted Protein A ligand patents, peer-reviewed HiPureA data, commercial DX licences and fresh hyaluronidase patent decisions are not the hallmarks of a shell. The problem is the gap between capability and commercial traction. Media and resin revenue is still too small to be disclosed separately. Meanwhile the fixed-cost base produced a FY2025 gross margin of about 13% and an operating margin of about –41%.
The financial position is the binding constraint. Negative operating cash flow, a litigated related-party loan and successive dilutive raises culminated in the August 2026 collapse of a control-transfer placement. That leaves the company without an anchor shareholder at a moment when large biologics customers will scrutinise supplier durability before qualifying a new media or resin vendor.
The Q2 2026 narrowing of the operating loss is the most constructive datapoint in two years. A P/B of about 0.59x embeds considerable pessimism, so the equity behaves like an option on two outcomes: a credible strategic investor arriving, and media and resin qualifications converting into recurring orders.
Until either is evidenced in filings, the appropriate stance is high-risk / speculative. Monitor quarterly operating losses, disclosed supply contracts and control-change filings rather than headline capacity claims.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / notes | Prior roles / background | Source |
|---|---|---|---|---|
Park Chul (박철; registered name 표쩌) | CEO and inside director | CEO since 2023. Supported the minority-shareholder campaign in 2025. Held about 0.3% in late 2024. | Previously led Amicogen China communications and operations (quoted as CEO on China results 2023) | [S-TOMATO], [S-DEAL1], [S-DAUM2] |
So Ji-sung (소지성) | Executive VP (총괄부사장), inside director | Elected Feb 2025; leader of the shareholder coalition; managing partner of Maga Partners | Minority-shareholder representative | [S-DEAL5], [S-FN25] |
Kim Jun-ho (김준호) | Head of Management Planning, inside director | Elected Feb 2025 | — | [S-DAUM2] |
Yoon Young-chul (윤영철) | Head of Production, inside director | Pre-2025 board member; ~0.1% holding | — | [S-DEAL1], [S-DAUM2] |
Lee Woo-jin (이우진) | Inside director (nominee Feb 2025) | Election not individually verified | — | [S-DEAL1] |
Byun Jang-woong (변장웅) | CEO, Puriogen | Since at least 2024 | Resin process specialist | [S-MG24] |
Kim Sang-jung (김상정) | President, BeyondCell | 2,024 | — | [S-MG24] |
Shin Yong-chul (신용철) | Founder; former Chairman/CSO | Removed as inside director 26 Feb 2025. THE VC lists him as co-CEO of Puriogen (May 2026); not confirmed in filings. | Founder 2000; Amicogen China chairman; Skinmed CEO | [S-DEAL1], [S-VC-P] |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Maga Partners Investment Association | 5.01% (2,754,541 shares) | Apr 2025 | [S-DEAL5] |
Shin Yong-chul (founder) | 3.69% (2,028,603 shares), down from 12.6% at end-Q3 2024 | Apr 2025 | [S-DEAL5], [S-DEAL1] |
Lysando AG | 2.7% | Sep 2023 | [S-KIRS] |
Treasury shares | 0.29% | 2026 | [S-BUT] |
Minority (retail) holders | 83.7% | Q3 2024 | [S-DEAL1] |
Foreign ownership | 6.22% | Dec 2023 | [S-KIRS] |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | HQ | Positioning vs Amicogen |
|---|---|---|---|
Pharma enzymes / biocatalysis | Novonesis (ex-Novozymes) | Denmark | Global industrial-enzyme leader; far larger scale |
| — | Codexis | US | Directed-evolution pharma biocatalysis peer (cited as comparator by [S-KOALA]) |
| — | DSM-Firmenich | Netherlands/Switzerland | Historic β-lactam enzymatic process know-how |
| — | Chinese enzyme makers (unnamed "copy enzymes") | China | Price competition that eroded CX sales [S-KIRS] |
Chromatography resins | Cytiva | US | Dominant Protein A supplier |
| — | Merck KGaA (MilliporeSigma) | Germany | Major resin and media supplier |
| — | Tosoh Bioscience | Japan | IEX/HIC/affinity resins |
| — | Bio-Works Technologies | Sweden | Partner and potential competitor |
| — | Chinese resin makers (e.g., Sunresin, Bestchrom) | China | Low-cost challengers in China; named here as industry context, not from sources |
Cell-culture media | Thermo Fisher, Merck, Lonza, Sartorius, Fujifilm Irvine Scientific | Global | KIRS names the global bioprocess leaders as holding about 75%+ of the materials market [S-KIRS] |
| — | Excell Therapeutics | Korea | Domestic media developer [S-KIRS] |
Health ingredients (collagen, NAG) | Gelatin and collagen majors (e.g., Gelita, Rousselot); Korean ODMs | Global / Korea | Commodity-like collagen competition; named as context |
Korean peer set (data provider) | Joa Pharm, HLB Pharm, Telcon RF Pharm | Korea | Small-cap pharma comparators [S-BULL-PEER] |
Peer Comparison FY2025
| Metric (FY2025) | Amicogen | Joa Pharm | HLB Pharm | Telcon RF Pharm |
|---|---|---|---|---|
Revenue (KRW 100M) | 420 | 593 | 2,056 | 432 |
Operating income (KRW 100M) | -171 | -66 | 11 | 7 |
Net income (KRW 100M) | -304 | -74 | 46 | -114 |
Operating cash flow (KRW 100M) | -244 | -42 | 6 | 17 |
Operating margin (%) | -40.8 | -11.1 | 0.5 | 1.7 |



